ODF2L and neoplasm: Consistently, we observed significantly increased overall survival (Figure 7D), diminished peritoneal hemorrhagic ascites, and reduced tumor nodule numbers (Figure 7E and Supplemental Figure 8A) in the combinatorial group of ODF2L loss and AZD1775 treatment.